207 related articles for article (PubMed ID: 10686061)
21. Evaluation of a multiplex human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus nucleic acid testing assay to detect viremic blood donors in northern Thailand.
Nantachit N; Thaikruea L; Thongsawat S; Leetrakool N; Fongsatikul L; Sompan P; Fong YL; Nichols D; Ziermann R; Ness P; Nelson KE
Transfusion; 2007 Oct; 47(10):1803-8. PubMed ID: 17880604
[TBL] [Abstract][Full Text] [Related]
22. Relative sensitivities of licensed nucleic acid amplification tests for detection of viremia in early human immunodeficiency virus and hepatitis C virus infection.
Busch MP; Glynn SA; Wright DJ; Hirschkorn D; Laycock ME; McAuley J; Tu Y; Giachetti C; Gallarda J; Heitman J; Kleinman SH;
Transfusion; 2005 Dec; 45(12):1853-63. PubMed ID: 16371038
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis B virus (HBV) DNA screening of blood donations in minipools with the COBAS AmpliScreen HBV test.
Kleinman SH; Strong DM; Tegtmeier GG; Holland PV; Gorlin JB; Cousins C; Chiacchierini RP; Pietrelli LA
Transfusion; 2005 Aug; 45(8):1247-57. PubMed ID: 16078909
[TBL] [Abstract][Full Text] [Related]
24. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors.
Busch MP; Glynn SA; Stramer SL; Strong DM; Caglioti S; Wright DJ; Pappalardo B; Kleinman SH;
Transfusion; 2005 Feb; 45(2):254-64. PubMed ID: 15660836
[TBL] [Abstract][Full Text] [Related]
25. Viral safety of solvent-detergent treated blood products.
Horowitz B; Prince AM; Horowitz MS; Watklevicz C
Dev Biol Stand; 1993; 81():147-61. PubMed ID: 8174797
[TBL] [Abstract][Full Text] [Related]
26. Pasteurized, monoclonal antibody factor VIII concentrate: establishing a new standard for purity and viral safety of plasma-derived concentrates.
Goldsmith JC
Blood Coagul Fibrinolysis; 2000 Mar; 11(2):203-15. PubMed ID: 10759015
[TBL] [Abstract][Full Text] [Related]
27. Multicenter performance evaluation of a transcription-mediated amplification assay for screening of human immunodeficiency virus-1 RNA, hepatitis C virus RNA, and hepatitis B virus DNA in blood donations.
Koppelman MH; Assal A; Chudy M; Torres P; de Villaescusa RG; Reesink HW; Lelie PN; Cuypers HT
Transfusion; 2005 Aug; 45(8):1258-66. PubMed ID: 16078910
[TBL] [Abstract][Full Text] [Related]
28. HIV-1, HCV and HBV seronegative window reduction by the new Roche cobas TaqScreen MPX test in seroconverting donors.
Wiedmann M; Kluwick S; Walter M; Fauchald G; Howe J; Bronold M; Zauke M
J Clin Virol; 2007 Aug; 39(4):282-7. PubMed ID: 17611148
[TBL] [Abstract][Full Text] [Related]
29. Magnetic bead technology in viral RNA and DNA extraction from plasma minipools.
Pichl L; Heitmann A; Herzog P; Oster J; Smets H; Schottstedt V
Transfusion; 2005 Jul; 45(7):1106-10. PubMed ID: 15987354
[TBL] [Abstract][Full Text] [Related]
30. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.
Terpstra FG; Parkkinen J; Tölö H; Koenderman AH; Ter Hart HG; von Bonsdorff L; Törmä E; van Engelenburg FA
Vox Sang; 2006 Jan; 90(1):21-32. PubMed ID: 16359352
[TBL] [Abstract][Full Text] [Related]
31. Identification of low HBV-DNA levels by nucleic acid amplification test (NAT) in blood donors.
Dettori S; Candido A; Kondili LA; Chionne P; Taffon S; Genovese D; Iudicone P; Miceli M; Rapicetta M
J Infect; 2009 Aug; 59(2):128-33. PubMed ID: 19586663
[TBL] [Abstract][Full Text] [Related]
32. Neopterin levels during the early phase of human immunodeficiency virus, hepatitis C virus, or hepatitis B virus infection.
Nübling CM; Chudy M; Volkers P; Löwer J
Transfusion; 2006 Nov; 46(11):1886-91. PubMed ID: 17076842
[TBL] [Abstract][Full Text] [Related]
33. Epidemiology of blood donors in Japan, positive for hepatitis B virus and hepatitis C virus by nucleic acid amplification testing.
Murokawa H; Yoshikawa A; Ohnuma H; Iwata A; Katoh N; Miyamoto M; Mine H; Emura H; Tadokoro K;
Vox Sang; 2005 Jan; 88(1):10-6. PubMed ID: 15663717
[TBL] [Abstract][Full Text] [Related]
34. Update on pathogen reduction technology for therapeutic plasma: an overview.
Solheim BG; Seghatchian J
Transfus Apher Sci; 2006 Aug; 35(1):83-90. PubMed ID: 16934528
[TBL] [Abstract][Full Text] [Related]
35. Experience of mandatory nucleic acid test (NAT) screening across all blood organizations in Germany: NAT yield versus breakthrough transmissions.
Nübling CM; Heiden M; Chudy M; Kress J; Seitz R; Keller-Stanislawski B; Funk MB
Transfusion; 2009 Sep; 49(9):1850-8. PubMed ID: 19453976
[TBL] [Abstract][Full Text] [Related]
36. HBV NAT positive [corrected] blood donors in the early and late stages of HBV infection: analyses of the window period and kinetics of HBV DNA.
Yoshikawa A; Gotanda Y; Itabashi M; Minegishi K; Kanemitsu K; Nishioka K;
Vox Sang; 2005 Feb; 88(2):77-86. PubMed ID: 15720604
[TBL] [Abstract][Full Text] [Related]
37. Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services.
O'Brien SF; Yi QL; Fan W; Scalia V; Kleinman SH; Vamvakas EC
Transfusion; 2007 Feb; 47(2):316-25. PubMed ID: 17302779
[TBL] [Abstract][Full Text] [Related]
38. External quality assessment for the detection of HCV RNA, HIV RNA and HBV DNA in plasma by nucleic acid amplification technology: a novel approach.
Pisani G; Marino F; Cristiano K; Bisso GM; Mele C; Luciani F; Wirz M; Gentili G;
Vox Sang; 2008 Jul; 95(1):8-12. PubMed ID: 18380770
[TBL] [Abstract][Full Text] [Related]
39. [Plasma fractionation. Progress, problems and perspectives].
Burnouf T
Ann Pharm Fr; 1994; 52(3):124-36. PubMed ID: 7998759
[TBL] [Abstract][Full Text] [Related]
40. Screening of blood donations by hepatitis C virus polymerase chain reaction (HCV-PCR) improves safety of blood products by window period reduction.
Hitzler WE; Runkel S
Clin Lab; 2001; 47(5-6):219-22. PubMed ID: 11405599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
